Study IDs predictors for ovarian cancer treatment decisions

08/5/2013 | Healio

Progression of disease and tumor characteristics can help determine how patients should be treated, according to new data. Patients with stage IIIC ovarian cancer and tumors of 45 mm or smaller attained greater benefit at five years from primary surgery, while those with stage IV disease and larger tumors showed better outcomes with neoadjuvant chemotherapy. The results appear in the European Journal of Cancer.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN